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ABSTRACT 
Aplastic (hypoplastic) anaemia (AA) is a rare condition that is characterised by pancytopenia 
in the peripheral blood, a hypocellular/acellular bone marrow and the absence of an abnormal 
infiltrate. Aplastic anaemia is classified as congenital/inherited and acquired. Acquired AA 
can be subdivided into idiopathic (primary) which is the most common form and secondary, 
depending on whether there is an identifiable cause. Inherited bone marrow failure 
syndromes are rare. 
Clinical and laboratory data implicate immune-mediated mechanisms in the pathogenesis of 
AA. Clinically AA manifests with features of bone marrow failure. Allogeneic 
haematopoietic stem cell transplantion is a potentially curable treatment in patients with 
severe AA who are candidates for transplantation. Immunosuppressive therapy with ATG as 
the backbone is effective in 60-80% of patients. 
The aim of this study was to document the demographic profile, clinical features, treatment 
modalities and outcome of patients diagnosed with AA who presented to the Clinical 
Haematology Unit at Chris Hani Baragwanath Academic Hospital and to compare it with 
studies done nationally and internationally. There is a paucity of studies on aplastic anaemia 
in South Africa. 
The data of patients diagnosed with aplastic/hypoplastic anaemia at the Clinical Haematology 
Unit of Chris Hani Baragwanath Academic Hospital were retrospectively reviewed and 
analysed.   
The majority of patients had idiopathic acquired aplastic anaemia (82%). The median age at 
presentation was 24.5 years and although a second peak occurring after 60 years is reported 
in the literature, there was no clear second peak in our patients. The male-to-female ratio was 
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1.7:1. The clinical presentation is similar to that reported in the literature with the most 
common presenting features being anaemia and bleeding. Infection was less common. 
The majority (69.9%) of patients had severe aplastic anaemia. The most common secondary 
cause was HIV accounting for 12% of patients. The clinical presentation was similar in both 
the HIV seropositive and HIV seronegative patients.  
Inherited bone marrow failure syndromes are rare. Two patients (2%) were confirmed 
genotypically to have Fanconi Anaemia. 
Allogeneic HLA-identical sibling stem cell transplantation is associated with a 75-90% 
probability of long-term cure. Most patients are candidates for a stem cell transplant but are 
excluded based on a lack of HLA compatibility. In this cohort, 2 patients underwent HLA-
identical haemopoietic stem cell transplantation with both achieving a complete response. 
Immunosuppressive therapy was given to the majority of patients. The overall response rate 
was 60.6% which largely reflects the response to immunosuppressive therapy as only 2 
patients underwent a stem cell transplant, and is similar to that reported in the literature. Less 
severe aplasia was associated with a better response. There were 3 (3%) patients who 
transformed to acute myeloid leukemia, 5 (5%) who developed haemolytic paroxysmal 
nocturnal haemoglobinuria and none who transformed to a solid malignancy. A significant 
number of patients (45%) were lost to long-term follow up. 
The 5 year survival probability was 69.2%. In studies from outside of South Africa, survival 
is reported to be 75-80% following immunosuppressive therapy. In the HIV positive patients, 
the 5-year survival probability was statistically significantly worse (37.5%) as compared to 
the HIV negative population (78.5%). There was a trend towards an inferior response (less 
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than partial or no response versus partial or complete response) in the HIV positive patients 
but this was not statistically significant.  
Survival was significantly associated with response to treatment. Patients who responded to 
treatment had a 5-year survival probability of 88.9% compared to 17.3% non-responders 
(p=0.0001). The leading cause of mortality was sepsis. 
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CHAPTER 1 
 LITERATURE  REVIEW 
Aplastic anaemia (AA) is defined as a pancytopenia with a hypocellular bone marrow in the 
absence of an abnormal infiltrate or marrow fibrosis. The diagnosis of aplastic anaemia 
requires at least two of the following: (a) haemoglobin <10g/dl,  (b) neutrophil count of   < 
1.5x10
9
/l and (c) platelet count < 100x10
9
/l. The severity of AA is assessed by the full blood 
count and bone marrow parameters according to the modified Camitta criteria (Camitta et al, 
1975).  
The incidence of AA is 2-3/ million population per year in Europe, but is higher in East Asia. 
There is a biphasic distribution with the first peak at 10-25 years and the second over 60 
years. There is no significant difference in incidence between males and females (Marsh et al, 
2009; Montane et al, 2008; Young et al 2008; Issaragrisil et al, 2006). 
Aplastic anaemia is classified as: i) primary- congenital (inherited) and acquired, idiopathic 
and ii) secondary (to a number of known causes). The majority (70 – 80%) of patients have 
acquired idiopathic AA (Marsh et al, 2009). 
 The inherited bone marrow failure syndromes (IBMFS) account for up to 15 – 20% of AA, 
the commonest being Fanconi anaemia (FA). Other IBMFS include Dyskeratosis congenita 
(DC), Shwachman-Diamond syndrome (SDS) and Congenital amegakaryocytic 
thrombocytopenia (CAMT). Secondary causes of bone marrow hypoplasia include: post viral 
infections (e.g. viral hepatitis, cytomegalovirus (CMV), Epstein-Barr virus (EBV), human 
immunodeficiency virus (HIV), parvovirus B19, drug induced (e.g. chloramphenicol, anti-
epileptics, anti-thyroid drugs, chemotherapy, etc.), radiation, toxins (e.g. solvents, benzene, 
pesticides, etc.), autoimmune disorders (e.g. SLE), paroxysmal nocturnal haemoglobinuria 
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(PNH), pregnancy and malignancies such as AML and hypocellular myelodysplastic 
syndrome (MDS) (Issaragrissil et al, 2006; Parker et al, 2005; Brown et al, 1997). 
The pathogenesis of acquired aplastic anaemia is unclear, although a number of potential 
mechanisms have been postulated. Bone marrow failure results from an insult to the 
haematopoietic cell compartment. On morphology, the bone marrow is replaced by fat. There 
is a significant reduction in CD34 positive cells and in vitro assays have suggested that the 
stem cell pool is greatly diminished in severe disease. Qualitative abnormalities such as 
shortened telomere length and a limited number of functional stem cells have also been 
implicated. Intrinsic stem cell defects are present in IBMFS. Aplastic anaemia does not 
appear to result from a defect in the bone marrow microenvironment as it can be cured by 
haematopietic stem cell transplantation suggesting that the defect is in the stem cell 
compartment (the “seed” rather than the “soil”) (Young, 2005).  
 The most widely accepted aetiopathogenetic mechanism of AA is that of an immune 
phenomenon in which cytotoxic T-cells are implicated. The evidence for this is that some 
patients with AA who were being prepared for stem cell transplantation with antithymocyte 
globulin (ATG) showed recovery in their marrow function (Young et al, 2006). Today ATG 
forms the backbone of immunosuppressive therapy for AA. Laboratory data also support an 
important role for the immune system in AA. The removal of T-cells from the bone marrow 
of patients with AA was associated with improved colony formation in vitro. Numerous 
cytotoxic T cells are found in AA and immunosuppressive therapy results in their reduction 
(Young, 2005). Cytotoxic T-cells produce cytokines like TNF alpha and INF gamma that 
targets self and inhibit the differentiation of the haemopoietic stem cells, inducing apoptosis. 
This ultimately results in critical loss of quantity and quality of the self-renewing 
haematopoietic multipotent stem cell compartment leading to bone marrow failure (Young et 
al, 2006).    
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Patients with aplastic anaemia most commonly present with features of bone marrow failure: 
symptoms and signs of anaemia, bleeding and infection. There is no lymphadenopathy or 
hepatosplenomegaly (Gordan-Smith et al, 1991). Bleeding is the most common presenting 
symptom. Patients present with easy bruising, gum bleeding, epistaxis, menorrhagia, 
petechiae, purpura and ecchymosis. There is also a risk of intracranial haemorrhage and 
retinal bleeds due to the thrombocytopenia. Symptoms of anaemia are frequent, and include 
fatigue, weakness, dyspnoea and palpitations. Infection is less commonly the presenting 
feature. Clinical findings are confined to the haematologic system unless there is a secondary 
cause for the AA such as systemic lupus erythematosis, HIV, etc. 
The clinical evaluation of aplastic anaemia has to include looking for features of IBMFS. 
This is essential for the appropriate management, education and genetic counselling. A family 
history of blood disorders, consanguinity, malignancy or congenital abnormalities may 
indicate the presence of an inherited bone marrow failure syndrome. 
The IBMFS have features unique to each syndrome. The physical findings in FA include 
short stature, pigmentary skin changes (hyper/hypo pigmentation), Fanconi “facies” including 
microcephaly, small eyes, epicanthal folds and abnormal positioning of the ears, and skeletal 
abnormalities mainly affecting the thumb and radius. Cardiac and renal anomalies (pelvic and 
horseshoe kidneys) also occur. Some patients with FA may have no apparent clinical 
abnormalities. FA is inherited in an autosomal recessive/X-linked recessive manner and 
mutations have been found in at least 15 genes.  There is an increased risk of MDS and acute 
myeloid leukemia (AML), as well as hepatic tumors and squamous cell carcinoma of the 
head and neck in these patients. The median age is 6.5 years with an equal male to female 
ratio (Shimamura et al, 2010). Chromosomes in FA are particularly susceptible to DNA 
cross-linking agents which forms the basis for a diagnostic assay. The FA genes play a role in 
the cellular response to DNA damage. Mutations in the FA genes leads to impairment in the 
4 
 
Fanconi anaemia- breast cancer (FA-BRCA) pathway, abnormal handling of oxidative stress, 
aberrant activation of mitogen activated protein kinases and defective telomere maintenance. 
The net impact of this is increased genomic instability and altered cell survival. 
A major cause of mortality in FA is bone marrow failure. Androgens such as oxymetholone 
and corticosteroids like prednisone improve haematopoietic function. Oxymetholone 
produces haematological responses in 50-70% of patients but its effects decrease over time. 
Side effects of oxymetholone include virilisation, liver dysfunction, hepatic tumors and 
peliosis hepatis. Haematopoietic stem cell transplant (HSCT) from a Human leucocyte 
antigen (HLA) -identical sibling donor is the treatment of choice. Reduced intensity 
conditioning regimens are used due to the hypersensitivity of FA cells. Long-term follow up 
of patients surviving HSCT show a high incidence of malignancies. The reasons for this 
include the inherent susceptibility to develop malignancy in FA patients and the use of 
radiotherapy as part of the conditioning. Hence conditioning regimens without radiotherapy 
are preferred. Gene therapy for the treatment of FA is still being explored (Dokal, 2011). 
 Dyskeratosis congenita has the diagnostic triad of nail dystrophy, reticular skin pigmentation 
and oral leucoplakia. These features may remain absent in a subset of patients. Its inheritance 
is autosomal dominant, autosomal recessive and X-linked. Like FA, there is an increased 
propensity to develop MDS/AML and solid tumors. Patients with DC are also predisposed to 
the development of pulmonary fibrosis. The median age is 14 years (Shimamura et al, 2010). 
Telomeres are very short in patients with dyskeratosis congenita due to germline mutations in 
telomere biology genes. In the majority of patients the telomere lengths are below the first 
percentile for age (Blanche et al, 2015). Telomerase is an RNA-protein complex that is 
important in maintaining telomere length after cell division. Some of the components of this 
complex include dyskerin, TERC, TERT, NHP2, NOP10. Mutations occurring in the 
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components of the telomerase complex and shelterin complex, as occurs in different subtypes 
of DC, result in telomere shortening. 
Improvement in haematopoietic function can be achieved in some patients with 
oxymetholone and growth factors (granulocyte colony stimulating factor [G-CSF] and 
erythropoietin). Their effectiveness is transient and the main treatment is allogeneic HSCT, 
which is the only curative treatment. As there is a predisposition to develop pulmonary 
fibrosis, drugs that are toxic to the pulmonary system should be avoided (Dokal, 2011).  
Shwachman Diamond Syndrome is characterised by neutropenia, pancytopenia, and exocrine 
pancreatic failure. It is inherited as an autosomal recessive disorder. There is an equal male to 
female ratio and an increased propensity to develop MDS/AML (Shimamura et al, 2010). 
Somatic abnormalities associated with SDS include short stature, protuberant abdomen, 
ichthyotic skin rash, hypertelorism, syndactyly, cleft palate and skin pigmentation. 
Neutropenia is the commonest cytopenia. The SBDS gene mutation is present in > 90% of 
patients with SDS. It is thought to play a role in ribosomal biogenesis and ribonucleic acid 
metabolism.  
Oral pancreatic enzymes are used to treat the malabsorption as a result of the pancreatic 
insufficiency. G-CSF may produce an improvement in the neutrophil count and the anaemia 
and thrombocytopenia may respond to oxymetholone. Allogeneic HSCT is also a treatment 
option (Dokal, 2011).  
The diagnosis of AA can only be confirmed by special investigations. The diagnostic work-
up of AA includes the exclusion of other possible causes of pancytopenia with a hypocellular 
bone marrow, exclusion of inherited AA, screening for an underlying cause of AA and the 
documentation of a co-existing abnormal cytogenetic or PNH clone. The Full blood count 
characteristically shows a pancytopenia. A normocytic or macrocytic anaemia with a 
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reticulocytopenia is present. A microcytic anaemia is uncommon, and its presence should 
lead one to suspect PNH. The bone marrow is hypocellular with increased fat spaces. 
Erythropoiesis, granulopoiesis and megakaryopoiesis is reduced to absent and macrophages, 
plasma cells and mast cells appear prominent. Dyserythropoiesis is common, but dysplastic 
megakaryopoiesis and granulopoiesis are not a feature of AA. There is no infiltrate or fibrosis 
on the trephine biopsy (Marsh et al, 2009). 
Screening for inherited disorders should be performed especially in children and in particular 
for the commoner FA and DC. A diagnosis of FA can be made by demonstrating increased 
chromosomal breakage following exposure of peripheral blood lymphocytes or skin 
fibroblasts to mitomicin C or diepoxybutane. Mutation analysis can also be undertaken for 
both FA and DC. Testing for the other IBMFS depends on clinical suspicion.  
Many drugs and chemicals have been implicated in the aetiology of aplastic anaemia, but for 
most drugs it may be difficult to prove causality (Issaragrisil et al, 1997). Drug classes that 
are associated with AA include: cytotoxics, antibiotics, anti-inflammatories, anti-convulsants, 
anti-thyroids, anti-depressants, and anti-malarials (Baumelou et al, 1993). Many 
chemotherapeutic drugs such as alkylating agents, antimetabolites, antimitotics cause bone 
marrow suppression as part of its toxic effects; these are dose-dependent, occur in most 
patients and are generally reversible. However, a number of drugs cause idiosyncratic 
reactions leading to AA without a clear dose-response relationship. Idiosyncratic drug 
reactions resulting in AA are rare and difficult to study (Young et al, 2006). Not all 
associations necessarily reflect causation as some drugs may have been used to treat 
symptoms of aplastic anaemia.  In principle, these drugs should be withdrawn and the patient 
monitored for improvement in the blood counts.  
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Epidemiologic data link benzene to AA (Smith et al, 1996). Benzene is also a cause of acute 
leukemia. In this regard an occupational history is important especially in industries where 
benzene is used as a solvent. Industries now regulate benzene exposure. It is noteworthy that 
benzene metabolites occur in some lead-free gasoline. Agricultural pesticides such as 
organochlorines, organophosphates as well as cutting oils and lubricating agents have also 
been associated with AA (Muir et al, 2003). 
Radiation can cause marrow aplasia as it damages DNA. The bone marrow is particularly 
susceptible as it has a high cell turnover. Radiotherapy can result in marrow aplasia 
especially where the radiation field involves large areas of bone marrow. It is dose-
dependent. Accidental exposure can occur in power plant workers, employees of hospitals, 
laboratories and industries such as food sterilization and metal radiography. There is an 
increased risk of haematologic and non-haematologic malignancies after radiation exposure 
(Young, 2005). 
Liver function tests are performed to detect hepatitis. Viral studies for hepatitis A, hepatitis 
B, hepatitis C, EBV, CMV, parvovirus B19 and HIV are performed to exclude a viral 
infection as a cause for the pancytopenia. Hepatitis is the commonest preceding infection 
accounting for up to 5% of patients. The marrow aplasia manifests 1-2 months after liver 
inflammation and usually in young men. The hepatitis is seronegative and is thought to be 
due to an as yet undiscovered virus. Parvovirus B19 is more commonly a cause of pure red 
cell aplasia rather than generalised bone marrow failure. 
  Vitamin B12 and folate levels are measured as severe megaloblastic anaemia can present 
with pancytopenia. The anti-nuclear antibody test is done to screen for autoimmune diseases. 
 AA can occur in systemic lupus erythematosis and eosinophilic fasciitis. Another 
immunologic disease which can result in aplasia is transfusion associated graft versus host 
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disease which may occur after transfusion of non-irradiated blood products to an 
immunodeficient recipient. 
Paroxysmal nocturnal haemoglobinuria (PNH) consists of a triad of features, viz. haemolytic 
anaemia, thrombosis and pancytopenia. It is an acquired condition due to a hematopoietic 
stem cell mutation defect. The defect in the phosphatidylinositol glycan class A (PIGA) gene 
results in an inability to synthesize glycosyl- phosphatidylinositol anchor that binds proteins 
to cell membranes. This results in cells deficient in complement-regulating surface proteins 
such as CD55 and CD59 which renders cells susceptible to intravascular haemolysis by 
complement proteins. Patients with PNH can develop aplastic anaemia and patients with 
aplastic anaemia can develop PNH. The Ham test and sucrose lysis tests have been used 
previously to detect PNH clones but have now been replaced by flow cytometry which is 
sensitive and quantitative. PNH clones have been detected in up to 50% of AA patients 
(Dunn et al, 1999). They are also seen in MDS. These clones may remain stable, regress or 
increase and some patients may develop haemolysis. Functional studies of bone marrow from 
patients with PNH, even those with predominantly haemolytic manifestations show defective 
haematopoiesis. One explanation for the aplastic anaemia/PNH syndrome is that the PNH 
clones are protected from immune-mediated destruction as they lack a GPI-anchored protein 
which may act as an autoantigen. 
Cytogenetic analysis of the bone marrow may be difficult as insufficient metaphases are 
obtained. Abnormalities of chromosomes 5 and 7 may suggest MDS. Abnormal cytogenetic 
clones may be present in 12% of cases with aplastic anaemia (Gupta et al, 2006). 
Patients with aplastic anaemia should be managed in a tertiary care centre. Management 
includes supportive care as well as specific therapy for the disease. Supportive care is 
essential to ensure that the patient survives to benefit from specific therapy. Support with red 
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cell and platelet transfusions is essential in patients with aplastic anaemia to maintain a safe 
blood count. Leucodepleted blood products should be used to reduce the risk of 
alloimmunisation and platelets should be single donor/ apharesis and irradiated (Marsh et al, 
2009; Killick et al, 1997). Alloimmunisation can result in an increased risk of graft rejection 
after allogeneic stem cell transplantation (Kaminsky et al, 1990). Cytomegalovirus (CMV) 
negative blood products should be given until the patients CMV status is known (Pamphilon 
et al, 1999). Repeated transfusions cause iron overload and iron chelation may be given to 
reduce the harmful effects of iron overload. It is usually indicated when the ferritin is 
>1000µg/l or there is evidence of organ dysfunction related to excess iron. Deferiprone is 
associated with agranulocytosis and is thus better avoided. Desferioxamine or the oral iron 
chelator deferasirox are suitable iron chelators. Platelet transfusions are given when the 
platelet count is <10x10
9
/l or <20x10
9
/l if the patient has pyrexia, sepsis, DIC or when the 
patient is bleeding. In patients with platelet refractoriness due to alloimmunisation, HLA 
compatible platelets are usually effective. Leucodepleted red blood cells are given when there 
is symptomatic anaemia (usually < 8g/dl) and to maintain a safe haemoglobin level. In 
patients with cardiac or pulmonary disease, a higher haemoglobin level may be required. 
As patients with AA are neutropenic, there is an increased risk of infection which is 
determined by the neutrophil count and the individual, with some patients having recurrent 
infections and others very few. Neutropenic patients are at an increased risk of bacterial and 
fungal infections (Ljungman 2000). Patients with severe neutropenia are given prophylactic 
antibiotics against gram negative bacteria and anti- fungal prophylaxis. Anti-viral prophylaxis 
and pneumocystis jirovecii prophylaxis are given in some centres during immunosuppressive 
therapy and post bone marrow transplant. For patients who have not undergone specific 
treatment, prophylactic antibiotics are considered for severe neutropenia and for patients who 
have frequent and/or severe infections. Active infection in the presence of neutropenia must 
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be aggressively treated empirically with parenteral, broad spectrum antibiotics. Specific areas 
of infection should be looked for on physical examination and radiographically in the 
neutropenic patient including oropharyngeal infections and anorectal abscesses, pneumonia, 
sinusitis and typhlitis (necrotizing enterocolitis). With contaminated indwelling catheters, 
gram positive cover with a drug such as Vancomycin should be added. Neutropenic patients 
are also susceptible to fungal infections (commonly Candida and Aspergillus) and a persistent 
fever on adequate antibacterial cover implies fungal disease. Timely initiation of antifungals 
should be undertaken.    
Haemopoietic growth factors alone do not form part of the specific treatment of severe 
aplastic anaemia as they are ineffective (Marsh et al, 2007). However, G-CSF may be used in 
patients with neutropenic sepsis not responding to antibiotics and antifungal agents as it may 
cause a temporary rise in the neutrophil count in patients with residual granulocytic activity.  
The standard treatment for a patient diagnosed with severe aplastic anaemia is either 
allogeneic stem cell transplantation from an HLA-identical sibling donor or 
immunosuppressive therapy (IST) with ATG and cyclosporin. Haematopoietic stem cell 
transplant from an HLA-identical sibling donor is the best treatment for the young patient. 
Transfusions of blood products from family members should be avoided to prevent 
sensitization to HLA antigens. In general, transfusions should be minimised as 
alloimmunisation may result in a higher risk of graft failure. In this regard, the search for a 
donor should be done as soon as possible and the transplantation should not be unnecessarily 
delayed. Patients with aplastic anaemia are followed up indefinitely as they may relapse or 
develop clonal disorders such as MDS, leukemia, PNH and solid tumors. The risk of clonal 
disease is 8% for MDS/leukemia (AML), 10% for haemolytic PNH and 11% for solid tumors 
at 11 years (Frickhofen et al, 2003). Repeat bone marrow examination is indicated if a clonal 
disease is suspected. 
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The outcome of HLA-identical sibling transplantation is a 75-90% probability of long term 
cure (Myers et al, 2009; Champlin et al, 2007; Kahl et al, 2005). Adverse factors that affect 
outcome after an allogeneic HSCT in AA include age > 40 years, prior failed 
immunosuppressive therapy, long interval between diagnosis and transplantation, a large 
transfusion burden and active infection prior to HSCT (Marsh et al, 2011). Graft failure 
occurs in 4-14%. Acute graft versus host disease (GVHD) is reported in 12-30% and chronic 
GVHD occurs in 30-40% of patients (Marsh et al, 2009b). 
 Allogeneic HLA-identical sibling donor stem cell transplantion is indicated in patients with 
severe or very severe aplastic anaemia, who are younger than 40 years of age and have an 
identical sibling match. Children with non-severe AA who are transfusion dependent and 
who have an HLA-identical sibling donor are also candidates for allogeneic HSCT. The cut-
off of 40 years is generally used as an older age is associated with a poorer outcome. 
However some centres transplant patients who are over 40 years of age (<55 years). The dose 
of haematopoietic stem cells for bone marrow transplantation is at least 3 x 10
8
 nucleated 
marrow cells/kilogram and for peripheral blood at least 2 x 10
6 
CD34+ cells/kg. Lower doses 
increase the risk of graft failure (Niederwieser et al, 1998; Russell et al, 1998). 
For patients with acquired aplastic anaemia, bone marrow transplants compared to peripheral 
blood stem cell transplants have been associated with less graft versus host disease 
(Schrezenmeier et al, 2007). The conditioning regimen recommended for patients <30 years 
of age is high dose cyclophosphamide 50mg/kg for 4 days and antithymocyte globulin (ATG) 
1.5 vials/10kg for 3 days if using Thymoglobuline, Genzyme together with 
methylprednisolone 2mg/kg for 3 days. Ciclosporin and methotrexate are used for GVHD 
prophylaxis. Allemtuzumab used as part of the conditioning regimen results in less GVHD. 
For patients > 30 years of age cyclophosphamide 1200mg/m
2
, fludarabine 120mg/m
2 
and 
either ATG or allemtuzumab is considered (Maury et al, 2007). Ciclosporin is usually tapered 
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after approximately one year to reduce the risk of late graft rejection which is associated with 
early discontinuation. Progressive mixed chimerism also predicts graft rejection and ideally 
chimerism should be monitored during tapering. If there is an increasing proportion of 
recipient cells, tapering must be delayed (Marsh et al, 2009b). 
GVHD is a serious complication as it adversely impacts on quality of life and survival, 
especially in AA where there is no benefit of having a graft- versus- disease effect. Risk 
factors for chronic GVHD include: acute GVHD, high marrow cell dose and use of peripheral 
blood stem cells (Schrezenmeier et al, 2007), older age, the use of ATG relative to an 
allemtuzumab-based conditioning regimen (Gupta et al, 2004) and complete donor 
chimerism.  
Risk factors for graft rejection include: alloimmunisation from multiple blood transfusions, 
low dose of donor haematopoietic stem cells, pretransplant and post transplant 
immunosuppression, T-cell depletion of donor marrow, donor –recipient gender mismatching 
and progressive mixed chimerism (Mcann et al, 2007; Stern et al, 2006). The treatment of 
graft rejection may include a second HSCT or if late graft failure occurred after withdrawal 
of ciclosporin, its reintroduction at therapeutic doses may result in a response. Complete 
recovery of autologous haemopoiesis may occur after graft rejection in some instances. 
Matched unrelated donor HSCT is an option for patients without a matched sibling donor. 
Outcomes have improved and have been attributed to the use of leucodepleted blood 
products, improved tissue typing and conditioning regimens (Maury et al, 2007). 
Umbilical cord blood is also a source of stem cells. It is associated with a lower risk of 
GVHD. However, due to the low number of haemopoiteic cells that is obtained from a 
donation, graft rejection is a major issue. 
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The long-term effects of HSCT may include infertility and an increased frequency of 
secondary solid malignancies when irradiation is used. Radiation has also been implicated in 
impaired growth and development in children (Socie et al, 2003; Socie et al, 1993). However, 
increasingly radiation-free regimens are being used. Fertility is usually preserved when using 
high dose cyclophosphamide and it is not necessary for sperm or oocyte cryopreservation 
pre-transplantation (Sanders et al, 1996). For patients using a fludarabine-based regimen 
there is currently insufficient data on fertility post transplant.   
For patients who are not eligible for a bone marrow transplant, immunosuppressive therapy 
using a combination of antithymocyte globulin (ATG) and ciclosporin is indicated. These 
include patients with non-severe aplastic anaemia who are transfusion dependent or have a 
neutrophil count of <0.5x10
9
/l; patients with severe or very severe AA who are older than 40 
years of age and younger patients who have no matched sibling donor. 
 ATG forms the backbone of immunosuppressive therapy. Both a horse and a rabbit 
preparation are available for use. The horse preparation (Lymphoglobuline) was generally   
the standard preparation used and the rabbit ATG (Thymoglobuline) was used if a second 
course of ATG was required (Scheinberg et al, 2006a). However, due to availability issues, 
usage of the rabbit ATG is increasing. The possible mechanisms of action of ATG include: T-
cell depletion by complement-mediated lysis; destruction of activated cytotoxic T 
lymphocytes by Fas-mediated apoptosis and antibody-dependent cellular cytotoxicity; 
reduced apoptosis and Fas expression on AA CD34+ bone marrow cells and direct 
stimulation of T-regulatory cells (Marsh et al, 2011). 
Side effects of ATG include allergic reactions such as fever and rigors, rash, and fluid 
retention. Anaphylaxis is possible and hence a test dose is usually given. Worsening 
thrombocytopenia requiring platelet transfusions often occurs due to the anti-platelet activity 
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of ATG. Serum sickness generally occurs 7 to 14 days after initiation of ATG. Steroids like 
methylprednisolone and prednisone, paracetamol and antihistamines are used for prophylaxis 
and alleviation of these manifestations. Ciclosporin can be started concomitantly with the 
ATG or after ATG. The dosage is adjusted to maintain adequate trough levels (150-
200ng/ml). There is a risk of relapse with rapid tapering of ciclosporin  (Saracco et al, 2008). 
Side effects of ciclosporin include hypertension, renal dysfunction, gum hypertrophy and 
neurotoxicity.  
Responses to immunosuppressive therapy takes 3-4 months to manifest and during this period 
supportive care has to continue. A second course of ATG can be given if there is no response 
to the first course or if there is a relapse after initial response to treatment.   
The use of ATG alone induces a partial response in 50% of patients. The response rate of 
ATG and ciclosporin is 60-80% with 5 year survival rates of 75-85% (Locasciulli et al, 2007; 
Bacigalupo et al, 2000a). Combined treatment is thus the standard for severe and very severe 
AA. Most patients receiving immunosuppressive therapy achieve a partial response 
(independence from transfusion and a neutrophil count adequate to prevent infection). 
Haematologic response strongly correlates with survival (Young, 2005). Relapse is common 
after IST, reported to be around 30% (Schrezenmeier et al, 1993). Relapse often occurs as 
ciclosporin is discontinued; some patients respond to reinstitution of ciclosporin and some are 
dependent on continuous use of ciclosporin.There is a 30-60% response rate to a second 
course IST (Tichelli et al, 1997). Patients are also at a risk of developing PNH, MDS and 
AML. Factors associated with a higher risk of developing clonal disorders include repeated 
courses of ATG, older age, high doses, use of G-CSF with ATG and ciclosporin, and 
shortened telomeres (Marsh et al, 2011). Mycophenolate mofetil (MMF), an 
immunosuppressive agent, has been used in patients refractory to ATG and cicolosporin, but 
has not shown good responses. The addition of MMF to ATG and ciclosporin has also not 
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resulted in better responses or a reduced relapse rate in AA (Schrezenmeier et al, 2003). The 
addition of sirolimus to ATG and ciclosporin has also not resulted in a significant difference 
in response. 
The use of immunosuppressive therapy in older patients is associated with a less favourable 
response and survival compared to younger patients (Tichelli et al, 1999). There is an 
increased risk of mortality from bleeding and infection in this population and there may also 
be an increased susceptibility to the side effects of ATG and ciclosporin. Co-morbid diseases 
are more prevalent in the older population as well. 
In patients with aplastic anaemia, small PNH clones are common (Socie et al, 2000). These 
clones may remain stable, increase or decrease in size. The patients with PNH clones are 
treated similarly to patients without a PNH clone. However, in haemolytic PNH, folate and 
iron supplementation may be required and prednisone and eculizumab are effective in 
reducing the haemolysis and thrombosis (Hill et al, 2005). 
Aplastic anaemia can present in pregnancy. The disease may remit spontaneously after 
termination of the pregnancy or after delivery. In patients who have responded to IST there is 
a significant chance of relapse (Tichelli et al, 2002). However, after successful allogeneic 
bone marrow transplant, relapse in pregnancy is uncommon (Kahl et al, 2005). Supportive 
care is the mainstay of treatment and ciclosporin is safe to use in pregnancy. 
The prognosis of AA initially was poor with rapid deterioration and death. The use of blood 
products and antibiotics provided some benefit but spontaneous recovery occurred in only a 
few patients. The prognosis of severe disease was worse than non-severe disease. Current 
treatment has significantly improved the outcome. Long-term survival is good with HLA-
matched sibling HSCT and IST. However, successful transplantation cures marrow failure 
whereas patients who receive IST remain at risk of relapse and malignant transformation. 
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Outcomes for matched unrelated donor HSCT is improving and it may become an important 
treatment modality in the future. The advancement in gene sequencing technologies may also 
make it easier to detect the IBMFS and may give us more insight into the pathogenesis of 
acquired AA.  
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CHAPTER 2 
PATIENTS AND METHODS 
The population studied consisted of patients diagnosed with aplastic / hypoplastic anaemia 
who presented to the Clinical Haematology Unit, Department of Medicine at Chris Hani 
Baragwanath Academic Hospital during the period 1 January 1995 to 31 December 2012. 
The inclusion criteria were: 
All patients with a confirmed diagnosis aplastic / hypoplastic anaemia using clinical, 
laboratory and bone marrow assessments. 
The exclusion criteria were: 
Patients not fulfilling the definition of aplastic / hypoplastic anaemia (ie. a peripheral 
pancytopenia together with a hypocellular / acellular bone marrow in the absence of an 
abnormal infiltrate or marrow fibrosis). 
The collection of data was done retrospectively from the patient files kept at the Haematology 
Unit at Chris Hani Baragwanath Academic Hospital. Laboratory data not found in the patient 
files were obtained from the hospital laboratory results electronic database. 
A data sheet (see appendix A and B) was used to obtain the relevant data for the study. This 
included the following information: demographics, clinical presentation, laboratory 
investigations, treatment, outcome, and follow up of patients. 
The computer programme Redcap was used to facilitate electronic data capture and for 
analysis. The data was subsequently exported from Redcap to Microsoft Excel where further 
data analysis was performed. GraphPad Prism version 6 was also used for some of the data 
analysis.  
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For the purposes of the study the following definitions were applicable: 
Definition of severity of Aplastic Anaemia (AA)  
Severe AA                                Bone marrow cellularity < 25%, or 25-50% with <30%  
(Camitta et al,1975)                 residual haemopoietic cells. 
                                                 2/3 of the following: 
                                                 Neutrophil count <0.5x10
9
/l 
                                                 Platelet count <20x10
9
/l 
                                                 Reticulocyte count <20x10
9
/l or corrected count <1% 
Very severe AA                       As for severe AA but neutrophils <0.2x10
9
/l 
Non severe AA                       Patients not fulfilling the criteria for severe or very severe AA 
 
The reticulocyte count was corrected for haemoglobin using the following formula: 
Corrected reticulocyte count = % reticulocytes x patients Hb/normal Hb 
The normal haemoglobin for a male was taken to be 14-18g/dl and for a female 12-16g/dl.  
The reticulocyte production index (RPI) was calculated as follows: 
RPI = % reticulocytes/maturation time x patients haematocrit/normal haematocrit. 
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The grading of the cytopenias was based on the WHO haematological toxicity scale 
demonstrated in the following table (Provan et al, 2009).  
Table 2.1         WHO haematological toxicity scale 
Parameter Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
Haemoglobin ≥ 11.0 9.5-10.9 8.0-9.4 6.5-7.9 <6.5 
Leucocytes ≥ 4.0 3.0-3.9 2.0-2.9 1.0-1.9 <1.0 
Neutrophils ≥ 2.0 1.5-1.9 1.0-1.4 0.5-0.9 <0.5 
Platelets ≥ 100 75-99 50-74 25-49 <25 
 
 Criteria for response to therapy in aplastic anaemia 
Less than a partial response / None:    Not meeting the criteria below 
Partial response:                                   Transfusion independent  
                                             No longer meeting criteria for severe AA 
Complete response:                              Haemoglobin > 10g/dl 
                                                              Neutrophil count > 1.0x10
9
/l 
                                                              Platelet count > 100x10
9
/l 
 
Definition of relapse 
Loss of a complete or partial response. 
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 CHAPTER 3 
RESULTS 
The records of patients with AA who presented to the Clinical Haematology Unit at Chris 
Hani Baragwanath Academic Hospital during the period 1 January 1995 – 31 December 2012 
(17 years) were reviewed. During this period, a total of 100 patients with AA were found. In 
view of the fact that this was a retrospective study, data were missing for some patients and 
the statistics were calculated based on the available data. For some statistics, the number of 
patients for whom data was available is indicated (e.g. symptoms in 99 rather than 100 
patients; see next page). There were 64 males and 36 females with a male to female ratio of 
1.77:1. The median age was 24.5 years (range 14-78 years). The median age for males was 
23.5 years (range of 14-78 years) and for females 26.5 years (range of 14-63 years). The peak 
frequency was in the second (28%) and third decade (42%). The age at presentation in the 
different decades is shown in Table 1.1. Eighty seven percent of patients presented before the 
age of 40 years. 
Table 3.1   Age at presentation 
Age ( years) Number Percentage 
10-19 28 28 
20-29 42 42 
30-39 17 17 
40-49 4 4 
50-59 3 3 
60-69 5 5 
70-79 1 1 
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The ethnicity profile of the patients was 92% black, 3% mixed ethnicity, 2% white and 2% 
asian. 
The most common symptoms were fatigue, occurring in 79.2% of patients and bleeding 
manifestations, occurring in 83.3% of patients. The symptoms at presentation are shown in 
Table 3.2. The most common symptoms were those related to anaemia and bleeding. 
Table 3.2        Symptoms at presentation 
Symptoms Number % 
Fatigue 76 79.2 
Dyspnoea 13 13.5 
Palpitations 2   2.1 
Dizziness 17  17.7 
Swelling of legs/body 8 8.3 
Fever 12 12.5 
Night sweats 8 8.3 
Bleeding 80 83.3 
Other (e.g. headache, weight 
loss) 
29  30.2 
 
The signs at presentation are shown in Table 3.3. The dominant clinical sign was pallor 
(anaemia) occurring in 92/99 patients (92.9%). Bleeding manifestations was the second most 
common clinical finding. Data was missing in 1 patient. 
Clinical features suggestive of IBMFS were noted in 7 patients, of which pigmentary changes 
was the commonest occurring in 5/7 patients (71%). 
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Table 3.3                   Signs at presentation in Aplastic Anaemia patients 
Signs Number Total (number) % 
Pallor 92 99 92.9 
Jaundice 2 99 2 
Fever 7 99 7 
Petechiae 37 99 37.3 
Purpura 11 99 11.1 
Ecchymosis 14 99 14.1 
Epistaxis 13 99 13.1 
Gum bleeding 27 99 27.2 
Lymphadenopathy 14 99 14.1 
Cardiac failure 3 99 3 
LRTI 5 99 5 
Hepatomegaly 3 99 3 
Splenomegaly 0 99 0 
Fundal changes 21 99 21.2 
Short stature 2 99 2 
Craniofacial 
dysmorphism 
1 99 1 
Pigmentary changes 5 99 5 
Nail dystrophy 1 99 1 
Leukoplakia 0 99 0 
Bone deformity 0 99 0 
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 Occupational, family and drug histories are shown in Table 3.4. There were 29/98 (29.6%) 
of patients who had a positive drug history. The drugs associated with AA in this cohort 
included antiepileptics, antibiotics, anti-inflammatories, illicit drugs and traditional/herbal 
substances. There were 5/98 (5.1%) who had a positive occupational history. These patients 
had exposure to petroleum products. None of the patients had a positive family history 
including those with IBMFS. 
Table 3.4                    Drug, occupational and family history 
History Number Total % 
Drug history 29 98 29.6 
Occupational history 5 98 5.1 
Family history 0 98 0 
 
The Full Blood Count and differential white cell count together with the reticulocyte count 
and reticulocyte production index is vital in the assessment and staging of Aplastic Anaemia. 
Table 3.5 shows details of these haematological parameters that are normally assessed in the 
work up and staging of an individual with suspected Aplastic Anaemia.  The variable, 
number of patients who had results available for the defined variable, the minimum and 
maximum value for the variable (range), the mean and the median are shown in Table 3.5. 
Some of the values were noted to be in the normal range. A possible explanation for this is 
that these patients were transfused with blood products prior to coming to Chris Hani 
Baragwanath Academic Hospital. However, on review, they fulfilled the criteria for the 
diagnosis of hypoplastic/aplastic anaemia.  
The grades of the cytopenias are shown in Table 3.6. This is based on the World Health 
Organisation (WHO) haematological toxicity scale. According to this scale; leucocytes, 
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haemoglobin, neutrophils and platelets are graded into five categories: Grade 0 to Grade 4 
based on their degree of severity (see Methods section). The majority of patients presented 
with Grade 3 and Grade 4 cytopenias. 
Table 3.5         Haematological characteristics of the patients at presentation 
Variable Number Minimum Maximum Mean Median 
White cell 
count 
(x10
9
/l) 
99 0.72 7.59 2.80 2.60 
Haemoglobin 
(g/dl) 
99 1.70 14.10 5.78 5.50 
Mean cell 
volume (fl) 
95 77.20 144.0 99.01 96.30 
Platelets 
(x10
9
/l) 
99 1.0 147 23.48 26.0 
Neutrophils 
(x10
9
/l) 
87 0.02 5.30 0.88 0.65 
Lymphocytes 
(x10
9
/l) 
86 0.02 4.14 1.61 1.57 
Corrected 
reticulocyte 
count (%) 
72 0 3.50 0.65 0.4 
RPI 73 0 1.80 0.34 0.20 
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Table 3.6                    WHO grades of the blood counts 
Variable Number 
(patients) 
Grade 0 
(%) 
Grade 1 
(%) 
Grade 2 
(%) 
Grade 3 
(%) 
Grade 4  
(%) 
Anaemia 99 2 4 12 19 62 
Leucopenia 99 18.2 20.2 31.3 25.3 5.1 
Neutropenia 87 11.5 5.7 10.3 28.7 43.7 
Thrombocytopenia 99 4 1 6.1 15.2 73.7 
 
The work up of a patient with suspected AA includes: 
I. Confirmation of the diagnosis of AA after excluding other causes of pancytopenia. 
II. Exclusion of secondary causes of bone marrow hypoplasia. 
III. Assessment of the severity of AA. 
IV. Exclusion of possible IBMFS. 
V. Documenting the presence or absence of a PNH clone. 
Table 3.7 shows the laboratory characteristics that were assessed at presentation. In the first 
column is the variable of interest together with a defined limit. The number of patients with 
the abnormality is shown in the second column, with the total number of patients tested for 
the defined variable in brackets. The percentage positive of the variable is noted in the third 
column and the mean value and range are shown in the subsequent two columns.  
The ferritin level was high in 89% of patients and low in only 1.2%.                     
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Table 3.7      Laboratory characteristics of  patients at presentation 
Variable Number % Mean Median Range 
Bilirubin 
Total 
bilirubin 
>21umol/l 
Direct 
bilirubin 
>6umol/l 
 
5 (82) 
 
 
 
 
9 (82) 
 
6 
 
 
 
 
11 
 
12.38 
 
 
 
 
5.88 
 
8.0 
 
 
 
 
3.0 
 
2-218 
 
 
 
 
1-196 
AST >40U/l 19 (81) 23.5 64.07 22.0 8-1315 
ALT >40U/l 17 (81) 20.9 74.93 19.0 5-1770 
Vitamin B12 
<145ng/l 
3 (86) 3.5 565.80 366.0 102-2000 
Firritin 
<30ng/l 
>150ng/l 
>1000ng/l 
 
1 (82) 
 
73 (82) 
 
20 (82) 
 
1.2 
 
89 
 
24.4 
900.82 453.50 15-10000 
RCF <55ng/l 5 (75) 6.7 1563.25 961.10 760-9718.90 
LDH 
>430U/l 
20 (47) 42.5 636.23 414 21.0-3918.0 
Alpha 
fetoprotein 
>6.6ku/l 
3 (18) 16.7 3.61 2.20 0.9-15.70 
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Table 3.8            Viral studies and ANF results of the  aplastic anaemia patients 
Investigation Positive (no.) Negative (no.) No result (no.) 
Hepatitis B 2 (2.9%) 69 29 
Hepatitis C 0 (0%) 69 31 
EBV 1 (1.8%) 57 42 
CMV 0 (0%) 55 45 
Parvo virus B19 0 (0%) 53 47 
HIV 12 (15.8%) 76 12 
ANF 1 (1.4%) 69 30 
 
Two patients were positive for Hepatitis B (2.9%), one for EBV (1.8%) and twelve patients 
for HIV (15.8%). The range of the CD4 (/µl) count was 4-840/µl with a mean of 309/µl and 
median of 275/µl. In Table 3.8, the percentages are calculated based on the number of 
available results and not the total number of patients. 
In patients for whom a PNH result was available in the patient records, a PNH clone was 
detected in 15/22 (68%) patients. The Hams test or more recently flow cytometry was used to 
confirm the diagnosis.   
Genetic tests for inherited bone marrow failure syndromes were documented in the files in 4 
patients. An abnormality was detected in 2 of the patients. One patient was homozygous for 
Fanconi Anaemia and the other had a deletion in one of the FANCG genes. In South Africa, 
Fanconi Anaemia occurs in the white Afrikaans population as a result of mutations in the 
FANCA gene and in the black population mutations have been found largely in the FANCG 
gene (Morgan et al, 2005; Tipping et al, 2001).  
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Results of the HLA studies done were available for 28 patients. A matched sibling donor was 
found in only 5/28 (17.8%) patients. 
The severity grading of aplastic anaemia is important for treatment decisions and is based on 
the blood count and bone marrow parameters (Camitta et al, 1975). The severity grading in 
the 100 patients reviewed in this study is shown in Table 3.9. In the first column is the 
severity, the second column contains the number of patients and the third is the percentage of 
all the patients who were classifiable.  
Table 3.9                 Severity grading of the aplastic anaemia patients (AA)  
Severity Number % 
Very severe AA 14 14 
Severe AA 44 44 
Non-severe AA 25 25 
Unclassifiable 17 17 
 
The majority of patients (58%) presented with severe and very severe AA. Seventeen patients 
were not classifiable due to insufficient data. If one excludes the patients who were 
unclassifiable due to missing data, then 69.9% would have severe and very severe AA.  
Patients with aplastic anaemia often require blood product support due to significant anaemia 
and thrombocytopenia. The blood product usage is shown in Table 3.10.  
 A mean of 21.04 units per patient of platelets and 18.52 units per patient of leucodepleted  
packed red blood cells were transfused during the entire course of illness. 
 
 
 
29 
 
 
Table 3.10                  Blood product usage in  patients with aplastic anaemia 
Blood product Number 
(patients) 
Minimum 
(units) 
Maximum 
(units)  
Mean 
(units) 
Median  
(units) 
Leucodepleted 
packed red 
blood cells 
95 0 222 18.52 8 
Platelets 95 0 263 21.04 9 
 
Growth factors were used in 3 patients and iron chelation in 11 patients.  
 
The standard regimen is a combination of ATG, ciclosporin with or without corticosteroids. 
The treatments received by the patients are documented in Table 3.11. 
Table 3.11              Specific treatment received by aplastic anaemia patients 
Treatment Number  % 
Stem cell transplant 2  2 
ATG + ciclosporin + 
prednisone 
56  56.5 
ATG +prednisone 7  7 
Ciclosporin +prednisone 21  21 
Prednisone 13  13 
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The 2 patients who had a SCT received prior immunosuppressive therapy. Eleven patients 
were given a second course of immunosuppressive therapy. Anabolic steroids were used in 
28 patients. In 3 patients the records were incomplete. 
The response to therapy is categorised into complete, partial and less than a partial response 
(see Methods for definitions). Table 3.12 shows these results.  
Table 3.12                Response to therapy  
Response Number % 
Complete response 35 35.4 
Partial response 25 25.3 
Less than a partial response 39 39.4 
 
The overall response rate was 60.6%. Twenty one (21%) patients relapsed. Three patients 
(3%) transformed to AML and 5 patients had associated haemolytic PNH. As far as the status 
of the patients at the last clinic or hospital visit is concerned; 25 had a complete response, 26 
had a partial response and 45 had less than a partial response. Of the 25 patients with a 
complete response, 10 were on treatment and 15 had been weaned off treatment. In the 
patients with a partial response, 19 were on treatment and 7 had been weaned off treatment.  
A total number of 45 patients were lost to follow-up. Twenty six patients demised. Of the 
patients who demised the mean survival was 30.4 months with a lower median of 14.5 
months. The main causes of death were infection/sepsis, bleeding and transformation to acute 
myeloid leukemia. 
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The response according to the severity of aplastic anaemia is shown in Table 3.13. The 
severity in 17 patients and the response in 1 patient could not be determined due to 
insufficient data.  
Table 3.13            Response according to the severity of Aplastic anaemia 
Severity Number Complete response Partial response Less than partial 
response 
Very severe AA 14  3 (21.4%) 1 (7.1%) 10 (71.4%) 
Severe AA 44 15 (34%) 15 (34%) 14 (32%) 
Non severe AA 24 12 (50%) 6 (25%) 6 (25%) 
 
In patients with severe aplastic anaemia, there was an even distribution in the number of 
patients who attained a complete, partial and less than partial response; whereas most patients 
with very severe aplastic anaemia obtained a less than partial response. In patients with non 
severe aplastic anaemia, 12/24 (50%) achieved a complete response.  
In table 3.14, the response according to the treatment modality is shown. The number of 
patients as well as the percentages achieving various degrees of response is shown. The 
degree of severity at diagnosis is also documented. The best response was seen in patients 
who underwent allogeneic stem cell transplantation with both achieving a complete response. 
The patients who received ATG, ciclosporin and prednisone had a response of 69.4%. 
Surprisingly, patients who had ciclosporin and prednisone had a better response (58.8%) than 
patients who received ATG and prednisone (16.6%), however this may be explained by the 
larger number of patients with very severe AA in the ATG group. Patients who received  
prednisone only had a response of 55.5%. The majority of these patients had non-severe AA. 
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Table 3.14             Response according to treatment modality 
Treatment 
modality 
Severity of AA Response to treatment Number 
of 
patients 
 Very 
severe 
Severe Non-
severe 
Complete Partial Less 
than 
partial 
 
Stem cell 
transplant 
0 2 
(100%) 
0 2 
 (100%) 
0 0 2 
ATG, 
ciclosporin, 
prednisone 
10 
(21.7%) 
27 
(58.6%) 
9 
(19.5%) 
20 
(43.4%) 
12 
(26%) 
14 
(30.4%) 
46 
ATG, 
prednisone 
2 
(33.3%) 
2 
(33.3%) 
2 
(33.3%) 
0  1 
(16.6%) 
5 
(83.3%) 
6 
Ciclosporin, 
prednisone 
1  
(5.9%) 
10 
(58.8%) 
6 
(35.3%) 
5 
(29.4%) 
5 
(29.4%) 
7 
(41,2%) 
17 
Prednisone 0 2 
(22.2%) 
7 
(77.8%) 
3 
(33.3%) 
2  
(22.2%) 
4 
 (44.4%) 
9 
 
To see if there was any relationship between the HIV status and response to treatment, the 
response in relation to HIV status was assessed. Twelve patients were positive, 76 patients 
were negative and the status in 12 patients was not known. The response in one HIV positive 
patient could not be assessed due to a lack of data. 
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Table 3.15     Response to treatment according to HIV status 
HIV status Number Complete response Partial response Less than partial 
response 
Positive 11 3 (27.3%) 2 (18.2%) 6 (54.5%) 
Negative 76 27 (35.5%) 20 (26.3%) 29 (38.2%) 
Unknown 12 5 (42%) 3 (25%) 4 (33.3%) 
 
The response to treatment in the HIV positive patients was less favourable than in the HIV 
negative population with more than 54.5% not attaining a partial or complete response as 
compared to 38.2% in the HIV negative patients (p: 0.33). However, this was not statistically 
significant due to the small number of HIV positive patients. The relative risk was 0.73 with a 
confidence interval of 0.33-1.43. 
Five (45.5%) of the HIV positive patients demised. Their average survival was 13.7 months 
with a range of 1.6-50 months. Fourteen (18.4%) HIV negative patients demised. Their 
average survival was 35.9 months with a range of 1.2-167 months. 
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Figure 1: Kaplan-Meier survival curve for patients with aplastic anaemia (1995-2012) 
The Kaplan-Meier survival curve is shown above (solid line) with the 95% confidence 
intervals (dotted lines). The horizontal lines are the censored variables.The 5-year survival 
probability was 69.2%. 
 
Figure 2: Kaplan-Meier survival curve according to HIV status 
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The above Kaplan-Meier survival curve compares the HIV negative (blue line) patients with 
the HIV positive patients (red line). The survival probability in the HIV patients is worse and 
is statistically significant (p value: 0.01).  The 5-year survival probability was 37.5% for the 
HIV positive patients and 78.5% in the HIV negative patients. 
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Figure 3: Kaplan-Meier survival curve in patients with AA according to Response 
 
The patients who responded (blue) had a better survival than the non-responders (red). The 5-
year survival probability was 88.9% compared to 17.3% respectively (p= 0.0001). 
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Table 3.16           Causes of death in patients with Aplastic anaemia 
Cause Number % 
Infection 16/26 61.5 
Haemorrhage 1/26 3.8 
Secondary malignancy 3/26 11.5 
Other 3/26 11.5 
Unknown 3/26 11.5 
 
The most common cause of mortality was infection accounting for 61.5% of all deaths. 
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 CHAPTER 4 
 DISCUSSION 
Aplastic anaemia is a rare disease with an incidence of 2-3 per million per year (Montane et 
al, 2008; Young et al, 2008, Montane et al, 2008). It is 2-3 times more common in Asia 
(Issaragrisil et al, 2006).  Most of the data on this disease are from North America, Europe 
and Asia. The aim of this study was to present the epidemiological, clinical and 
haematological features, the treatment modalities and the outcomes of patients with Aplastic 
anaemia at Chris Hani Baragwanath Academic Hospital (Johannesburg, South Africa). 
One hundred patients were reviewed over a period of seventeen years. The average number 
of patients seen per year was 5.8. The majority of patients were of black ethnicity (92.9%). 
Aplastic anaemia is typically a disease of young individuals with the peak incidence 
occurring between 10-25 years. A second peak at 65 years is described in the literature 
(Heimpel, 2000). The median age at diagnosis in this study was 24.5 years and there was no 
clear second peak. The majority of cases (42%) presented between 20-30 years. The male to 
female ratio is equal in some studies and other studies report either a male or female 
predominance depending on the geographical area. There was a male predominance in this 
cohort of patients with a ratio of 1.7:1 which is similar to a previous study done on aplastic 
anaemia at this centre which reported a male-to-female ratio of 2.15:1 (Patel, 1994).  
Anaemia was the dominant clinical sign occurring in 92.9% of patients followed by signs of 
mucocutaneous bleeding. These included petechiae, purpura, ecchymoses, epistaxis and gum 
bleeding. Of note, fundal haemorrhages occurred in 20% of patients. A fever was 
documented in only 7% of patients at presentation. Lymphadenopathy and 
hepatosplenomegaly are not features of aplastic anaemia unless there is a concomitant 
infection or a secondary cause of AA (Gordan-Smith et al, 1991). 
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 Hepatomegaly was evident in 3 (3%) of the patients. One of the patients was HIV positive 
and had concomitant tuberculosis which could explain the reason for the hepatomegaly, the 
second patient was positive for hepatitis B and no obvious cause could be determined in the 
third. 
 Lymphadenopathy was documented in 14 (14%) patients. Five of these patients were HIV 
positive, 2 had tuberculosis, one had tonsillitis and another presented with pneumonia. There 
was no clear explanation in the other 5 patients. 
There were two patients who had jaundice at presentation. In one patient it was due to 
haemolytic PNH and the other patient had deranged liver function tests with the ALT and 
AST raised more than the GGT and ALP. Hepatitis studies and viral studies for EBV, CMV, 
HIV, Parvovirus B19 were negative in this patient. There was, however, a significant alcohol 
history, and the liver dysfunction resolved spontaneously. 
 Clinical features suggestive of an IBMFS were present in 7 patients of which skin 
pigmentary changes and short stature were the commonest manifestations. Results of genetic 
studies which were available for 2 patients confirmed FA. 
 A number of drugs and toxins have been associated with aplastic anaemia. These are based 
mainly on case reports and case control studies (Issaragrisil et al, 1997; Kauffmann et al, 
1996; Baumelou et al, 1993). Drugs which are associated with aplastic anaemia and were 
taken by some patients in this study included: sulphonamides (bactrim), anti-malarials 
(quinine) was used in a patient who developed malaria, antihypertensive agents (thiazides), 
anti-convulsants (phenytoin, carbamazapine), and anti-inflammatory agents. There were five 
patients who had an occupational history where exposure to substances associated with 
aplastic anaemia may have occurred. These included: exposure to benzene, petroleum 
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products and agricultural pesticides. There was no history of prior exposure to radiation, 
cytotoxic or chemotherapeutic agents in this cohort. 
None of the patients had an autoimmune disorder. One patient was positive for ANF (titre of 
1:40) but had no clinical features of a rheumatological disorder.  
Aplastic anaemia can manifest for the first time in pregnancy and there is an increased risk of 
relapse after immunosuppressive therapy in a patient with aplastic anaemia during pregnancy. 
Supportive care is the mainstay of treatment (Kwon et al, 2006; Tichelli et al, 2002). 
Ciclosporin has been used safely in pregnancy. Four patients were diagnosed with aplastic 
anaemia during pregnancy. Two patients were treated with ciclosporin and prednisone and 
two with prednisone only. One patient obtained a complete response and subsequently had an 
uneventful second pregnancy. Two patients obtained a partial response and one patient 
relapsed after a partial response. 
 Clones of paroxysmal nocturnal haemoglobinuria (PNH) cells are characterised by a 
deficiency of glycosylphosphatidylinositol-anchored proteins on the cell surface due to an 
acquired mutation of the PIG-A gene on the X chromosome. This results in increased 
susceptibility to complement-mediated lysis due to a deficiency of CD 55 and CD 59 on the 
cell membranes. The response to immunosuppressive therapy is not different in patients with 
or without a PNH clone (Scheinberg, et al, 2010) and these patients are treated no different to 
patients without PNH clones which can occur in 40-50% of patients with aplastic anaemia. In 
most patients, the clone remains subclinical. Clinical features such as haemolysis and 
thrombosis is seen in only a few patients and occurs more commonly in those patients with 
large clones (>50% of cells). Fifteen out of 22 patients for whom PNH results were 
documented had PNH clones. Five patients had features of haemolysis. None of them had 
thrombosis.  The clone size ranged from 1.1-95%. In 3 patients with haemolytic PNH the 
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clone size was >50% and in 2 patients it was <50%. The prevalence of PNH clones could not 
be determined due to insufficient data.  
Hepatitis-associated aplastic anaemia is described in the literature as a syndrome of bone 
marrow failure occurring 2-3 months after an episode of acute hepatitis. The cause is often 
uncertain and patients are negative for Hepatitis A, B and C viruses. Brown et al, 1997 
reported a series where there was good response to immunosuppressive therapy (Brown et al, 
1997). In this review there were two patients who had hepatitis B. Both had severe aplastic 
anaemia. One of the patients was also diagnosed with HIV, had an infiltrative picture on liver 
function tests and a chest X-Ray in keeping with tuberculosis. He was initiated on anti-TB 
therapy. The patient was also started on ciclosporine and prednisone but was lost to follow-
up. The second patient had unremarkable liver function tests. Immunosuppressive therapy 
was given with a poor response. There was one positive result for EBV. There were no 
positive results for Hepatitis A, hepatitis C or Parvovirus B19. 
Haematologic manifestations of HIV (i.e. cytopenias) are common and include anaemia, 
neutropenia, lymphocytopenia and thrombocytopenia. They have a multifactorial aetiological 
basis. Aplastic anaemia due to HIV is rare and there is a paucity of data regarding this 
association in the literature. However, there has been a case report of aplastic anaemia due to 
HIV in a child who responded to antiretroviral therapy (Shah et al, 2005). HIV1, subtype C, 
the most common subtype in southern Africa, has also been shown to infect haematopoietic 
progenitor cells in a study conducted in Botswana, resulting in higher rates of anaemia 
(Andrew et al, 2007). It remains uncertain at this stage whether HIV is a cause of aplastic 
anaemia or is coincidental as both diseases affect teenagers and young adults. 
There were 12 patients who were HIV positive. The grades of cytopenias were similar to the 
HIV negative subset manifesting predominantly with grade 3 and grade 4 anaemia, 
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neutropenia and thrombocytopenia. There did not appear to be any obvious relationship 
between the development of aplastic anaemia and the CD 4 count. The mean CD4 count was 
309x10
6
/l with a range of 4-840x10
6
/l and a median of 274.5x10
6
/l. The response to therapy 
appeared to be less favourable in HIV seropositive patients compared to seronegative patients 
with a complete response achieved in 27.3% versus 35.5% and a partial response of 18.2% 
versus 26.3% respectively. There were 54.5% of HIV positive patients and 38.2% of HIV 
negative patients who had less than a partial response. The survival also appeared worse in 
the HIV positive subset. Sepsis was the cause of death in all 5 patients with HIV, who 
demised. Four of the five patients died in the first year of diagnosis. Three patients were 
diagnosed with tuberculosis (TB); 2 with pulmonary TB and 1 with TB lymphadenitis. Only 
three patients were on combined antiretroviral therapy prior to the diagnosis of aplastic 
anaemia. ATG, cyclosporine and prednisone were given in 4 patients; 2/4 patients achieved a 
complete response and 2/4 had less than a partial response. Cyclosporine and prednisone was 
given in 6 patients; 1 had a complete response, 2 had a partial response and 3 had less than a 
partial response. In one patient prednisone was given with no response.  
Supportive care with blood products in order to maintain a safe blood count is part of the 
management of aplastic anaemia. Prophylactic platelet transfusions are given when the 
platelet count is <10x10
9
/l or <20x10
9
/l in the presence of fever/sepsis/DIC, and are 
invariably given in response to bleeding manifestations (Kelsey et al, 2003). Fatal 
haemorrhages are more common when the platelet count is <10x10
9
/l. Packed red blood cells 
are given to maintain the haemoglobin >8g/dl, depending on co-morbidities especially 
cardiorespiratory. Leucodepleted packed red blood cells and single donor platelets which are 
leucodepleted and irradiated are routinely given in order to prevent alloimmunisation which 
may result in increased graft rejection and platelet refractoriness in multi-transfused patients. 
Irradiated blood products prevent Transfusion Associated Graft-Versus Host Disease as AA 
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patients are candidates for stem cell and bone marrow transplants. The average number of 
platelets transfused per patient during the course of disease was 21.04 with a median of 9 and 
packed red blood cells 18.52 with a median of 8. Iron chelation in the form of deferrioxamine 
was given to 11 patients. The number of packed red blood cells transfused in these 11 
patients ranged from 16-222 per patient during their treatment course. 
It is necessary to determine the severity of aplastic anaemia as it is important with regard to 
treatment decisions. Severe and very severe aplastic anaemia is treated with haemopoietic 
stem cell transplantation; either an HLA identical sibling donor or a matched unrelated donor 
or anti-thymocyte globulin (ATG)-based immunosuppressive therapy (IST). The use of ATG 
and ciclosporine has resulted in a significant improvement in haematopoietic recovery and 
survival. In severe aplastic anaemia, the response rate to ATG alone is less than the 
combination of ATG and cyclosporine (Bacigalupo et al, 2000a) and the response to ATG 
and ciclosporine is greater than ciclosporine alone in non-severe aplastic anaemia (Marsh et 
al, 1999). In the majority of cases, IST is used initially as most patients are not suitable 
candidates for stem cell transplanion due to lack of a suitable donor, age and co-morbidities. 
In this review, 53% of patients presented with severe aplastic anaemia and 16.9% with very 
severe aplastic anaemia. Thirty percent had non- severe aplastic anaemia. In a study done in 
2007 where 2479 consecutive patients with AA were analysed using data from 257 centers 
reporting to the European group for Blood and Marrow Transplantation Severe Aplastic 
Anaemia Working Party between 1991-2002, 1421 patients had data on severity. There were 
40.8% who had VSAA, 24.4% with SAA and 34.6% with moderately severe AA (Locasciulli 
et al, 2007). It appears that severe and very severe aplastic anaemia is common in both 
settings. In this study, there were 87 (87%) patients who were ≤ 40 years making them 
eligible for SCT based on age; and based on severity criteria, 69.9% of patients who were 
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classifiable were potential SCT candidates. However, HLA sibling matches were found in 
5/28 patients for whom results were available and is a major limiting factor. 
 Only 2 patients underwent HLA compatible sibling SCT. The first was a 20 year old male 
with SAA who initially received ATG. He had complete HLA compatibility with his sister 
and attained a complete response following alloSCT. He developed mild to moderate chronic 
graft vs host diseases which was controlled on therapy and he has a follow up of 11 years 
without relapse. The second was a 17 year old female patient with SAA who also received 
IST initially. She subsequently underwent a SCT as HLA studies revealed a 10/10 match with 
her sister. A complete response was attained. Complications included: acute GVHD, CMV 
infection and therapy-related hypertension. Unfortunately she demised 10 months later from a 
drug overdose (unrelated to aplastic anaemia). Her blood counts were normal at the time of 
her death. Both patients received cyclophosphamide and fludarabine as part of their 
conditioning regimen. 
Immunosuppressive therapy was used in 97 patients. ATG, ciclosporine and prednisone was 
given in the majority (56). However, 7 patients were given ATG and prednisone, 21 
ciclosporine and prednisone and 13 prednisone only. Results using immunosuppression with 
ATG and ciclosporine are good and this regimen is considered the standard protocol. The 10 
year actuarial survival in patients receiving first line immunosuppressive therapy is 80% in 
children and 70% in adults (Locasciulli et al, 2007). A second course of ATG was given to 11 
patients: 7 of which relapsed and 4 who did not respond to the first course of ATG. Of the 
non-responders, only 1 patient had a partial response. Of those who relapsed, 4/7 (57%) of 
the patients responded. The response rate to a second course of IST is between 30-60% with 
the response being better in previous responders compared to non-responders. All 4 of the 
patients who responded previously attained a complete response. 
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A complete response occurred in 35/99 (35.4%), a partial response in 25/97 (25.3%) and a 
less than partial response in 39/97 (39.4%).Thus, the overall response rate was 60.6% which 
is comparable to that reported in the literature from studies in Europe and the USA. 
Immunosuppressive therapy using ATG and ciclosporine is associated with response rates of 
60-80% (Bacigalupo et al, 2000b). Responders (complete and partial response) had a better 
survival when compared to non-responders with a cumulative survival probability at 5 years 
of 88.9% and 17.3% respectively (p=0.0001).  There were 16/26 (61.5%) deaths that occurred 
in the non-responders. The inferior survival in non-responders was also found by Scheinberg 
et al, 2006a where re-treatment with IST in patients who had refractory or relapsed disease 
was being evaluated. (Scheinberg et al, 2006a). In the HIV positive patients, the response was 
less favourable than the HIV negative patients with 54.5% not achieving a response 
compared to 38.2% (p: 0.33). One possible explanation for the poor response in this study 
could be the high rate of early deaths with 33% mortality in the first year in the HIV positive 
patients.  
There were 21 patients out of 60 patients who responded initially and subsequently relapsed 
(35%). Among the complete responders relapse occurred in 14 of 35 (40%) and in 7 of 25 
(28%) of partial responders. The mean time to relapse was 33.13 months with a range of 2.7-
82.1 months. Relapse is reported to occur in approximately 10- 30% (Schrezenmeier et al, 
1993; Bacigalupo et al, 2000b). 
Patients are at risk for clonal disease and follow-up of these patients should be life-long. In 
this study, 45 patients were lost to long-term follow-up, which is significant. The median 
duration of follow-up was 23.4 months with a mean of 40.6 months. Three patients 
transformed to acute myeloid leukemia (AML) and all 3 demised subsequently. The times to 
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transformation after the diagnosis of aplastic anaemia were 3months, 2years 7 months and 2 
years 10 months.  Two of the patients attained partial responses and relapsed prior to their 
transformation to AML and 1 patient had less than a partial response. The transformation rate 
has been reported to be 8% for MDS/AML at 11 years (Frickhofen et al, 2003). This is higher 
than was noted in our setting in which only 3/100 (3%) patients were reported to have 
transformed to AML. The same study reported transformation to solid tumours to be 11%. 
There was no transformation to solid tumours in this study.  
The overall 5-year survival in this study was 69.2%. In the literature, the long-term survival 
probability is 70-85% using immunosuppressive therapy. There is not much data on survival 
in the setting of HIV and aplastic anaemia. The survival in HIV positive patients was 
significantly worse with a survival probability at 5 years of 37.5% compared to 78.5% in the 
HIV negative population (p:0.01). The majority of deaths occurred in the first year (4/5 
patients demised in the first year). All the deaths were due to sepsis. The majority of deaths in 
this cohort (HIV positive and negative) were due to infection (61.5%). Fatal haemorrhage 
occurred in 1 patient and malignancy accounted for 3 deaths; all transforming to acute 
myeloid leukemia.  
   
 
   
 
 
 
46 
 
 
CHAPTER 5 
CONCLUSION AND LIMITATIONS OF THE STUDY 
This study was conducted with the objective of obtaining data regarding the demographics, 
clinical presentation, treatment, complications and outcome of patients with aplastic anaemia 
at the Clinical Haematology Unit at Chris Hani Baragwanath Academic Hospital. 
The clinical presentation was similar to that of other studies reported in the literature with 
features of anaemia and bleeding manifestations predominating. The severity of AA was also 
similar with most of the patients classified as severe and very severe aplastic anaemia. 
Acquired idiopathic aplastic anaemia was the commonest. The most frequent secondary 
causes of aplastic/hypoplastic anaemia were HIV, pregnancy and hepatitis B respectively 
accounting for 18% of the patients. Congenital AA was diagnosed in 2 (2%) patients.  
Immunosuppressive therapy was the mainstay of treatment. Haematopoietic stem cell 
transplantation with a HLA matched sibling donor was the treatment modality in the minority 
of patients. The reasons for this are the low number of patients with siblings from the same 
parents and low number of patients with HLA compatibility. Matched unrelated donor 
transplantation was not done. Searching for a matched unrelated donor is not feasible for 
financial reasons at our public sector hospital. 
The response rate, relapse rate and overall survival are similar to that reported in the 
published literature from studies done in Europe and the USA. Transformation occurred in a 
few patients to acute myeloid leukemia and to PNH. The rate of transformation was less in 
this study relative to that reported in the literature. 
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The most common cause of mortality was infection. HIV positivity and non-response to 
therapy were associated with inferior survival.  
With regards to HIV positive patients, the clinical presentation was similar to HIV negative 
patients. The CD4 counts are variable, and most patients were not on antiretroviral therapy at 
the time of diagnosis. All were treated with immunosuppressive therapy and none underwent 
transplantation. There was a high rate of early mortality due to infection and the overall 
survival was inferior to the HIV negative patients. 
 
LIMITATIONS 
It was a retrospective study conducted at a single institution. Data collection was dependent 
on the patient files and some of the data was missing. The institution serves the Soweto 
region which is constituted predominantly of patients of black ethnicity and it is possible that 
the findings may be different in other regions in South Africa. 
Compliance remains a major problem at this hospital with a significant number of patients 
being lost to long term follow- up. 
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AGE:
GENDER:
ETHNICITY:
CLINICAL PRESENTATION 
 
HISTORY NO Yes
      SYMPTOMS : FATIGUE:
DYSPNOEA:
PALPITATIONS:
DIZZYNESS:
SWELLING:
FEVER:
NIGHT SWEATS:
BLEEDING:
OTHER:
NO Yes
ANTIBIOTICS:
ANTI-INFLAMMATORY:
ANTI-CONVULSANTS:
ANTI-THYROIDS:
ANTI-MALARIALS:
OTHER:
NO Yes
    FAMILY  HISTORY:
NO Yes Details(if Yes)
OCCUPATIONAL/ENVIRONMENTAL EXPOSURE:
        BENZINE AND OTHER SOLVENTS:
        AGRICULTURAL PESTICIDES:
        CUTTING OILS AND LUBRICATING AGENTS:
        RECREATIONAL DRUGS:
        OTHER:
Details(if Yes)
Details(if Yes)
Details(if Yes)
APPENDIX A: DATA SHEET
STUDY NUMBER:
DRUG HISTORY :
CLINICAL  EXAMINATION NO Yes
      PALLOR:
      FEVER:
      INFECTION:
      PETECHIAE
      PURPURA:
      ECCHYMOSIS:
      FUNDAL CHANGES:
      EPISTAXIS:
      GUM BLEEDING:
NEUROLOGICAL-FALLOUT
      OTHER:
Details(if Yes) 
APPENDIX B:                                     FLOW  CHART  OF  INVESTIGATIONSFLOW CHART OF INVESTIGATIONS
Initial Best Response                  Last Visit / Loss toLast Vi it/Loss to
Presentation                                                                        follow up / DeathFollow up /death
Duration
from initial
presentation
WCC
RCC
HCT
HB
MCV
PLATELETS
NEUTROPHILS
LYMPHOCYTES
EOSINOPHILS
BASOPHILS
MONOCYTES
BLASTS
SMEAR
COMMENTS
CORRECTED
RETICULOCYTE
COUNT
RPI
NA
K
UREA
CREATININE
SERUM FE
%SATS.
TRANSFERRIN
FERRITIN
RED CELL FOLATE
VIT. B12
HEP. A ANTIBODY
HEP B s Ag
HEP. B cAb
HEP. B s Ab
HEP. C ANTIBODY
ANA
CMV
EBV
PARVOVIRUS B 19
HIV
CD4 COUNT
( IF + )
VIRAL LOAD
( IF + )
TOTAL BILIRUBIN
DIRECT BILIRUBIN
TOTAL PROTEIN
ALBUMIN
ALP
GGT
AST
ALT
LDH
ds - DNA
u - HAEMOSIDERIN
HAPTOGLOBIN
                                                                          
                     
BONE  MARROW  ASPIRATE  AND  TREPHINE
CELLULARITY …………………………………………………………………..
ERYTHROPOIESIS …………………………………………………………………………………………..
GRANULOPOIESIS …………………………………………………………………………………………..
MEGAKARYOPOIESIS …………………………………………………………………………………………..
LYMPHOCYTES ……………………………………………………………………………………………………………
PLASMA CELLS …………………………………………………………………………………………………………..
MONOCYTES …………………………………………………………………………………………………………..
MACROPHAGES …………………………………………………………………………………………………………..
OTHER / ABNORMAL CELLS ………………………………………………………………………..
FIBROSIS ………………………………………………………………………………………………………….
CONCLUSION …………………………………………………………………………………………………………
CHEST X -RAY :....................................................................................................................................................................................................................................................
ABDOMINAL ULTRA SOUND :.............................................................................................................................................................................................................................
OTHER IMAGING :.................................................................................................................................................................................................................................................
CHEST X -RAY :....................................................................................................................................................................................................................................................
ABDOMINAL ULTRA SOUND :.............................................................................................................................................................................................................................
OTHER IMAGING :.................................................................................................................................................................................................................................................
TRANSFORMATION:
NO YES DURATION FROM DIAGNOSIS OUTCOME
    TO MDS:
     TO AML: 
     TO HAEMOLYTIC PNH:
     TO SOLID TUMOURS:
TREATMENT
    SUPPORTIVE THERAPIES:
     
     TRANSFUSIONS:
LEUCODEPLETED PACKED CELLS
SINGLE DONOR PLATELETS
GRANULOCYTE TRANSFUSIONS
   GROWTH  FACTORS: NO YES
        G-CSF:
        IRON CHELATOR:
SPECIFIC TREATMENT INCLUDING DATE OF INITIATION AND TERMINATION:
  NO YES INITIATION TERMINATION
   HLA - IDENTICAL SIBLING DONOR:
   ATG AND CYCLOSPORIN:
   MATCHED UNRELATED DONOR:
   CYCLOSPORIN:
   OXYMETHALONE:
   SUPPORTIVE THERAPY:
   OTHER:
TIME  TO  PARTIAL  RESPONSE  FROM INITIAL  TEATMENT  DATE:  .............................................................
QUANTITY FREQUENCY INDICATIONS
DETAILS(IF YES)
TIME  TO  COMPLETE  RESPONSE  FROM  INITIAL  TREATMENT  DATE: .......................................................
 RELAPSE:                       N0O YES DETAILS
CURRENT STATUS:
NO YES DETAILS
COMPLETE RESPONSE:
PARTIAL RESPONSE OFF TREATMENT:
PARTIAL RESPONSE ON TREATMENT:
DEATH:
DATE OF DEATH : .....................................................................................................................................................
CAUSE OF DEATH : ...................................................................................................................................................  
SURVIVAL ( DATE OF HISTOLOGICAL DIAGNOSIS UNTIL DATE OF DEATH ) : ................................................................
   LOSS TO FOLLOW UP:
LAST DATE PATIENT SEEN : .......................................................................................................................................
STATUS OF PATIENT AT THAT DATE : ........................................................................................................................
OTHER:
TIME  TO  PARTIAL  RESPONSE  FROM INITIAL  TEATMENT  DATE:  .............................................................
TIME  TO  COMPLETE  RESPONSE  FROM  INITIAL  TREATMENT  DATE: .......................................................
DATE OF DEATH : .....................................................................................................................................................
CAUSE OF DEATH : ...................................................................................................................................................  
SURVIVAL ( DATE OF HISTOLOGICAL DIAGNOSIS UNTIL DATE OF DEATH ) : ................................................................
LAST DATE PATIENT SEEN : .......................................................................................................................................
STATUS OF PATIENT AT THAT DATE : ........................................................................................................................
